A Phase II Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients with Malignant Melanoma Pre-Treated with Recombinant CDX-301, a Recombinant Human Flt3 Ligand
Conferences
Bhardwaj, N; Ernstoff, M; Curti, B; Hanks, BA; Albertini, M; Luke, J; Yellin, M; Keler, T; Davis, T; Vitale, L; Crocker, A; Friedlander, P ...
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Location
Chicago, IL
Conference Name
2016 American Society of Clinical Oncology Annual Meeting
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Bhardwaj, N., Ernstoff, M., Curti, B., Hanks, B. A., Albertini, M., Luke, J., … Fling, S. (n.d.). A Phase II Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients with Malignant Melanoma Pre-Treated with Recombinant CDX-301, a Recombinant Human Flt3 Ligand. Presented at the 2016 American Society of Clinical Oncology Annual Meeting, Chicago, IL.
Bhardwaj, N., M. Ernstoff, B. Curti, B. A. Hanks, M. Albertini, J. Luke, M. Yellin, et al. “A Phase II Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients with Malignant Melanoma Pre-Treated with Recombinant CDX-301, a Recombinant Human Flt3 Ligand,” n.d.
Bhardwaj N, Ernstoff M, Curti B, Hanks BA, Albertini M, Luke J, et al. A Phase II Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients with Malignant Melanoma Pre-Treated with Recombinant CDX-301, a Recombinant Human Flt3 Ligand. In.
Bhardwaj N, Ernstoff M, Curti B, Hanks BA, Albertini M, Luke J, Yellin M, Keler T, Davis T, Vitale L, Crocker A, Friedlander P, Morishima C, Cheever M, Fling S. A Phase II Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients with Malignant Melanoma Pre-Treated with Recombinant CDX-301, a Recombinant Human Flt3 Ligand.
Location
Chicago, IL
Conference Name
2016 American Society of Clinical Oncology Annual Meeting
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis